Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Bezafibrate to prevent relapsing pancreatitis in WAGR syndrome
  1. Daniela Diacono1,
  2. Andrew Fagbemi2,
  3. Joanne Puleston3,
  4. Indraneel Banerjee1
  1. 1Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK
  2. 2Department of Paediatric Gastroenterology, Royal Manchester Children's Hospital, Manchester, UK
  3. 3Department of Gastroenterology, Manchester Royal Infirmary, Manchester, UK
  1. Correspondence to Dr Indraneel Banerjee, indi.banerjee{at}cmft.nhs.uk

Summary

Recurrent episodes of acute, severe pancreatitis are a feature of the rare WAGR congenital anomaly syndrome. Although pancreatitis is well recognised as a life-threatening association of WAGR syndrome, treatment to prevent pancreatitis is not recommended. We report the successful prevention of hypertriglyceridaemia-associated relapsing pancreatitis in a child with WAGR syndrome with Bezafibrate. In addition to dietary fat restriction, Bezafibrate may be a useful therapeutic adjunct in WAGR related relapsing pancreatitis.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.